治疗原发性震颤的当前和未来神经药理学选择。
Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.
机构信息
Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, Spain.
University Institute of Molecular Pathology Biomarkers, UNEx. ARADyAL Instituto de Salud Carlos III, Caceres, Spain.
出版信息
Curr Neuropharmacol. 2020;18(6):518-537. doi: 10.2174/1570159X18666200124145743.
BACKGROUND
Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data.
METHODS
A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019.
RESULTS
To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful.
CONCLUSION
Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABAA receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future.
背景
特发性震颤（ET）可能是最常见的运动障碍。在这篇综述中，我们总结了目前治疗这种疾病的药理学选择，并讨论了一些源自 ET 实验模型中测试的药物或神经病理学数据的未来选择。
方法
使用 PubMed 数据库，从 1966 年至 2019 年 7 月 31 日，对特发性震颤的药理学进行了文献检索。
结果
迄今为止，β受体阻滞剂普萘洛尔和抗癫痫药扑米酮是治疗 ET 疗效较高的药物。在 ET 患者中测试的其他药物显示出不同程度的疗效或没有效果。
结论
肉毒杆菌毒素 A 注射可能对一些对药物治疗有抵抗力的 ET 患者有用。根据最近的神经化学数据，作用于 extrasynaptic GABAA 受体、谷氨酸能系统或 LINGO-1 的药物可能是未来有前途的治疗选择。
Zotero 插件